Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Botulinum Toxin Type A for Injection to Treat Glabellar Lines

NCT02303002 is registered in ClinicalTrials.gov with Revance Therapeutics, Inc. as lead sponsor.

NCT NCT02303002
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02303002 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Botulinum Toxin Type A for Injection to Treat Glabellar Lines
Lead sponsor
Revance Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2014
Completion date
January 31, 2016
Enrollment
268 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glabellar frown lines